Emerging Talent Symposia (scheduled as of
Nov. 19, 2021 JST/UTC+9)
1. ETS 1
Virtual LIVE: November 20 (Sat) 8:30 - 9:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Lung development and regeneration
Session
summary: The number of patients with severe lung
diseases such as pulmonary hypertension, interstitial pneumonia, and COPD is
increasing and there is a growing demand for lung regeneration. In recent
years, researches on lung development and regeneration
were remarkably progressed and lung regeneration is no longer a dream while it
is still challenging. In this session, we invited three young world-leading
researchers to overview the fundamental mechanisms of lung development and
regeneration. We also would like to discuss about cutting edge technologies to
explore this research filed such as single-cell
sequencing and blastocyst complementation.
Chairs: Tatsuya
Nagano (Kobe
University Graduate School of Medicine, Japan)
Mitsuru Morimoto (RIKEN Center for Biosystems Dynamics Research, Japan)
1)
Lung development and regeneration
Mitsuru Morimoto (RIKEN Center
for Biosystems Dynamics Research, Japan)
2)
Genetic and cellular mechanisms that underlie the complex orchestration of
alveolar
morphogenesis
Nan Tang (National
Institute of Biological Sciences, Beijing, China)
3)
Advances in human lung generation
Munemasa Mori (Columbia
Center for Human Development, Columbia University Medical Center, USA)
Virtual LIVE: November 20
(Sat) 8:30 - 9:25 (JST/UTC+9)
On-demand: November 26 –
December 28, 2021
Potential platforms for understanding the
mechanism of lung diseases
Session summary: There have been limited platforms for elucidating the mechanism of lung
diseases, because of the difficulty to recapitulate and analyze the functions
of lung constituent cells in experimental settings. However, recent
technological breakthroughs push this field forward to be more comprehensive
and practical for community. In this session, we introduce synergistic
combinations of imaging strategy, artificial intelligence, in silico
simulation, stem cells, genome editing or microfluidics devices, leading to the
new paradigm of lung research. Advances of cell and molecular biology of the
lung are the expected area these days and we wish that our research progress
would be beneficial for society.
Chairs: Shimpei
Gotoh (Kyoto University, Japan)
Elisa Herawati (Sebelas Maret
University, Indonesia)
1) iPS cell-based disease
modelling of primary ciliary dyskinesia
Naoyuki Sone
(Department of
Respiratory Medicine, Graduate School of Medicine, Kyoto University, Japan)
2) Fast AI-Enabled Cell Tracking and Migration
Analysis for High-Throughput Drug
Screening
Alphons R Gwatimba (Telethon Kids Institute, Australia)
3) In vivo and in vitro models
of functional airway epithelium
Elisa Herawati (Sebelas Maret University, Indonesia)
3. ETS 3
Virtual LIVE: November 20 (Sat) 8:30 - 9:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Insights into pathophysiology of respiratory
illnesses
The pathophysiological findings from COVID-19
Session
summary: Human �ｿｽgcommon cold�ｿｽh
coronaviruses (HCoV) have epitopes with cross-reactivity to the homologous in
SARS-CoV-2, causing Coronavirus disease 2019 (COVID-19). SARS-CoV-2 infection
is associated with chronic as well as acute lung disorders, especially after moderate
to severe pneumonia. Since many people likely have experienced infections with
one of HCoV strain, extensively explored findings from clinical features of
pulmonary sequelae and pathophysiology of COVID-19 during the global pandemic
may give us insights on mechanisms underlying respiratory diseases or
conditions with unknown causes. In this session, a comprehensive review of the
current literature on post-COVID-19 pulmonary sequelae, pathophysiology during
acute COVID-19 infection from clinical findings will be introduced and opened
up for discussion.
Chairs: Masaki
Yamamoto (Yokohama
City University Medical Center, Japan)
Yen Hsiang Huang (Taichung Veterans General Hospital, Taiwan)
1)
COVID-19 Lung Sequelae: Clinical Updates
Matsuo So (Department
of Medicine, Icahn School of Medicine at Mount Sinai, USA)
2)
The pathophysiological findings from COVID-19
Masaki
Yamamoto (Yokohama City University Medical Center, Japan)
4. ETS 4
Virtual LIVE: November 20 (Sat) 8:30 - 9:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Prognosis of interstitial lung diseases
Session summary: Interstitial lung disease
(ILD) is a heterogeneous group of diseases characterized by inflammation and
fibrosis of the lung parenchyma. These include connective tissue
disease-associated ILD, fibrotic hypersensitivity pneumonitis, and
unclassifiable ILD. In each ILD, predicting the behavior and progression of the
disease is important for treatment management decisions. In recent years,
several biomarkers have been proposed in clinical trials to predict the course
of ILD. In this symposium, we will focus on the following points. Prognosis of
acute exacerbation on ILD. Prognosis of ILD associated with systemic sclerosis.
Prognosis of ILD associated with rheumatoid arthritis.
Chairs: Kensuke Kataoka (Tosei General Hospital, Japan)
Nicole S. Goh (Austin Hospital, Australia)
1)
Prognosis of acute exacerbation of interstitial lung diseases
Kensuke Kataoka (Tosei General Hospital, Japan)
2)
Prognosis of interstitial lung disease associated with systemic sclerosis
Nicole S. Goh
(Austin Hospital, Australia)
3)
Prognosis of interstitial lung disease associated with rheumatoid
arthritis
Song Yee Kim (Yonsei
Univerisity College of Medicine, South Korea)
5. ETS 5
Virtual LIVE: November 20 (Sat) 8:30 - 9:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Up-to-date knowledge of management of NTM
pulmonary disease
Session
summary: NTM pulmonary diseases,
especially MAC and M. abscessus species, have increased and have become a
significant public health issue in Asian Pacific countries. Treatment of NTM
pulmonary disease should be based on the "ATS/ERS/ECSMID/IDSA clinical
guideline." Furthermore, care providers need to understand the clinical
phenotypes and natural course of NTM pulmonary disease because the patients'
characteristics are different in the countries, and it needs a customized
approach in each clinical setting. Dr. Asakura will present the results of
cluster analyses of the Japanese NTM and BE registry. Dr. Jo will teach us how
to follow the patients based on each clinical phenotype. Lastly, Dr. Burke will
summarize the current standard and tell us the future treatment strategies of
this disease.
Chairs: Kozo Morimoto (Fukujuji Hospital, Japan
Anti-Tuberculosis Association, Japan)
Jing Zhang (Zhongshan
Hospital, Fudan University, China)
1)
Clinical phenotype of bronchiectasis with NTM pulmonary disease. The story
in Japan
Takanori Asakura (Keio
University School of Medicine, Japan)
2)
Natural course of NTM pulmonary disease. When to start treatment to whom?
Kyung-Wook Jo (University
of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea)
3)
Treatment of NTM pulmonary disease. Current recommendation and future
direction
Andrew Burke (The Prince
Charles Hospital, Australia)
6. ETS 6
Virtual LIVE: November 20 (Sat) 9:30 - 10:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Bronchopulmonary dysplasia in adult: the early origins
of adult lung disease
Session
summary: Bronchopulmonary dysplasia
(BPD) is a chronic respiratory disease occurring in approximately 10-30% of
preterm infants especially born before 28 weeks of gestation. The mortality
rate of infants with BPD has improved over the past three decades owing to the
progress of neonatal intensive care. Conversely, the prevalence of BPD has been
increasing because of the trend toward high-risk pregnancies and extremely
lower birth weights. Adults born preterm with BPD show impaired lung function,
bronchial asthma, emphysema, or pulmonary fibrosis. It is thus important to
share the pathophysiology of BPD as the early origins of adult lung disease. In
the present session, BPD will be discussed from the neonatologist�ｿｽfs, the
pathologist�ｿｽfs, and the pulmonologist�ｿｽfs points of view.
Chairs: Chiharu Ota (Tohoku
University Hospital, Japan)
Shannon J Simpson (Telethon Kid Institute, Australia)
1)
Bronchopulmonary dysplasia-from the neonatologist�ｿｽfs point of view
Fumihiko Namba (Saitama
Medical Center, Saitama Medical University, Japan)
2)
Bronchopulmonary dysplasia-from the pathologist�ｿｽfs point of view
Ryoko
Saito-Koyama (Department
of Pathology, Tohoku University Graduate School of Medicine, Japan)
3)
Bronchopulmonary dysplasia-from the pulmonologist�ｿｽfs point of view
Shannon J Simpson (Telethon Kid
Institute, Australia)
7. ETS 7
Virtual LIVE: November 20 (Sat) 9:30 - 10:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
CPAP adherence across the world
Session
summary: CPAP has been established as
a standard therapy for patients with OSA. However, important clinical issues to
be solved include its poor acceptance and adherence. According to a large body of previous
studies, CPAP adherence has been reported 40-80% depending on the study. In
2008, the US Centers for Medicare and Medicaid Services (CMS) issued the CPAP
adherence threshold for the first 90 days to continue to use CPAP under
insurance coverage, which is ≥4 hrs of use on 70% of nights. Different from the
US, other countries have their own health insurance system. Thus, we have to
know CPAP adherence data in various countries. Additionally, it is helpful to
know the strategies to improve CPAP adherence in each country.
Based on this background,
the purpose of this symposium is to address issues related to CPAP adherence and
strategy to improve CPAP adherence such as telemedicine across the world.
Chairs: Motoo Yamauchi (Nara Medical
University, Japan)
Naricha Chirakalwasan (Faculty of Medicine, Chulalongkorn University, Thailand)
1)
Real World Data for CPAP adherence in Japan
Eriko Hamada (Nara Medical
University, Japan)
2)
Efficacy of a telemonitoring system in CPAP therapy
Worawat
Chumpangern (Faculty of
medicine, Khon Kaen university, Thailand)
3)
Real world data for CPAP adherence in the US
Sanjay R. Patel (University
of Pittsburgh, USA)
8. ETS 8
Virtual LIVE: November 20 (Sat) 9:30 - 10:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Multidisciplinary approaches for pleural
effusions
Session
summary: Pleural effusion has
differential diagnoses, which includes malignant pleural effusion (i.e., lung
cancer, malignant mesothelioma, and pleural metastasis from other organs),
tuberculous pleuritis or empyema/parapneumonic effusion caused by other
bacteria, and benign transudative effusion because of hypoalbuminemia and heart
or renal failure. Thus, multidisciplinary approaches for pleural effusion are
imperative for rapid diagnosis. Here, we present the useful methods for
evaluating the etiologies for pleural effusions using by ultrasound and fluid
parameters.
Chairs: Takeshi Saraya (Kyorin University School of
Medicine, Japan)
Hoang Anh Duc (Respiratory
Center – Bach Mai hospital, Hanoi Medical University, Hanoi, Vietnam)
1)
Clinical Features and Prognosis of Nontuberculous Mycobacterial Pleuritis
Kazuma Yagi (Keio
University School of Medicine, Japan)
2)
Diagnostic method for malignant pleural effusion distinguishing malignant
mesothelioma from lung cancer using pleural carcinoembryonic antigen and
hyaluronic acid levels
Takeshi Saraya (Kyorin University School of
Medicine, Japan)
3)
Ultrasound for respiratory disorders: Pleural effusions, Covid-19, and
more
Taro Minami (Care New England
Medical Group, The Warren Alpert Medical School of Brown University, USA)
9. ETS 9
Virtual LIVE: November 20 (Sat) 9:30 - 10:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Frontiers in pulmonary hypertension
Session summary: The
pathophysiology of pulmonary hypertension (PH) is wide-ranging and associate
with intricately intertwined mechanisms. There have been a lot of things to
clarify in the field which could lead to improved prognosis of PH. This symposium
will ask three expert speakers to give special lectures on the latest clinical
findings and research of chronic thromboembolic pulmonary hypertension,
interstitial lung disease-PH, and pulmonary arterial hypertension. Through this
symposium with their lectures, the so-called �ｿｽgfrontier�ｿｽh, we would like to have
lively discussions with all that would contribute to the bright future of PH
treatment.
Chairs: Ayako Shigeta (Chiba
University, Japan)
Kuo Yang Wang (China
Medical University Hospital, Taiwan)
1)
Inflammatory biomarkers and characteristics in Japanese CTEPH patients
Akira Naito (Graduate
School of Medicine, Chiba University, Japan)
2)
Pulmonary hypertension in interstitial lung diseases
Ping-Hung Kuo (National
Taiwan University Hospital, Taiwan)
3)
Is Nintenidab Effective as a Treatment for Pulmonary Hypertension? -Pros
and Cons-
Tetsutaro Nagaoka (Juntendo
University, Japan)
10. ETS 10
Virtual LIVE: November 20 (Sat) 9:30 - 10:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Basophils and mast cells in airway diseases
Session summary: Basophils and mast cells
have high-affinity receptor for IgE and have been recognized as
allergy-associated cells. However, recent studies have revealed unique aspects
of basophils and mast cells in chronic inflammatory diseases beyond
IgE-mediated inflammation. In this session, we will focus on the impact of both
cells in asthma and COPD. In the ILC2-dependent asthma model, basophils
cooperate with ILC2 to exacerbate eosinophilic inflammation. Whereas, in the
COPD model, basophils contribute to the development of emphysema. Sputum
genetic analysis is a promising method to detect rare cells and may open new
horizons for understanding the role of basophils and mast cells in human
diseases.
Chairs: Keiko
Wakahara (Nagoya
University Graduate School of Medicine, Japan)
Hiroki Kabata
(Keio University School of Medicine, Japan)
1)
Basophils in COPD
Sho Shibata (Tokyo
Medical and Dental University, Japan)
2)
Sputum mast cell/basophil gene expression in severe asthma
Michael Fricker (University of Newcastle, Australia)
3)
ILC2 and basophils in asthma
Takahiro
Matsuyama (Graduate School of Medical and Dental
Sciences, Kagoshima University, Japan)
11. ETS 11
Virtual LIVE: November 20 (Sat) 10:30 - 11:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Mitochondria in lung disease
Session
summary: Mitochondria are a
distinguishing organelle of eukaryotic cells. Although best known for their
critical role in energy production via oxidative phosphorylation, mitochondria
are also essential for regulating critical cellular processes, such as cell
death and inflammation, and are hotspots for reactive oxygen species
production. Accumulating evidence suggests that mitochondrial DNA (mtDNA) acts
as a damage-associated molecular pattern that can drive molecular processes
leading to inflammatory responses. In this symposium, we will invite young
investigators whose research focuses on mitochondria as pro-pathogenic
mediators in lung disease. Their lectures will highlight the latest trends in
this field and discuss the involvement of mitochondria as well as mtDNA in the
pathogenesis of lung diseases.
Chair: Kenji
Mizumura (Nihon
University School of Medicine, Japan)
Jin Woo Song (Asan Medical Center, University of Ulsan
College of Medicine, South Korea)
1)
Mitochondria in COPD
Kenji Mizumura (Nihon University
School of Medicine, Japan)
2)
Mitochondria in IPF
Jin Woo Song (Asan Medical
Center, University of Ulsan College of Medicine, South Korea)
3)
Mitochondrial DNA in lung disease
Suzanne Cloonan (Trinity
College, Dublin, Ireland and Weill Cornell Medicine, USA)
12. ETS 12
Virtual LIVE: November 20 (Sat) 10:30 - 11:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Minding Sex/ Gender as a Biological Variable in
Lung Disease
Session
summary: The sex-based difference in
terms of risk for diseases, epidemiology, phenotypes, and clinical outcomes has
been consistently observed yet fully understood or acknowledged. ETS12 provides
scientific aspects of sex-based differences and approaches in various lung
diseases, mainly focusing on asthma, COPD, and interstitial pneumonia.
This session aims to deepen
the knowledge of sex/gender in medicine and address the importance of including
sex/gender in biomedical research. The target audience of this session is
scientists, clinical researchers, clinicians, medical students, and any other
respiratory care team members who are involved in patient care and
clinical/scientific research.
Chairs: Mari Hikichi (Nihon
University School of Medicine, Japan)
Annalicia Vaughan (Centenary UTS Center for Inflammation, Australia)
1)
Intrstitial pneumonia
Mari Hikichi (Nihon
University School of Medicine, Japan)
2)
Sex-based difference in disease behavior of COPD and asthma
Fanny Wai San Ko (The Chinese University
of Hong Kong, Hong Kong)
3)
Importance of including sex and gender in biomedical research
Neeloffer
Mookherjee (University
of Manitoba, Canada)
13. ETS 13
Virtual LIVE: November 20 (Sat) 10:30 - 11:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Secondary Infections in COVID-19 patients
Session
summary: This session features the
characteristics of secondary infections in COVID-19 by integrating speakers
from Japan, Thailand and India. We will present the frequency and
microbiological characteristics of secondary bacterial infections in COVID-19
patients with acute respiratory failure, derived from the largest national
registry database, COVIREGI-JP in Japan. The experience of a large number of HIV-positive
COVID-19 patients in Thailand will also provide insight into the management and
concerns of immunocompromised COVID-19 patients. The mucormycosis epidemic in
COVID-19 patients resulting in high morbidity and mortality in India will share
the clinical characteristics on this patient population, tips for diagnosis,
and treatment.
Chairs: Kazuko Yamamoto (Nagasaki
University Hospital, Japan)
Romanee Chaiwarith (Chiang Mai University, Thailand)
1)
Bacterial and fungal infection in COVID-19 patients- experience from Japan
Kazuko Yamamoto (Nagasaki
University Hospital, Japan)
2)
Secondary infections in HIV-positive COVID-19 patients
Romanee Chaiwarith
(Chiang Mai University, Thailand)
3)
Mucormycosis in COVID-19 patients- experience from India
Atul K Patel (infectious
Diseases Clinic, Ahmedabad, India)
14. ETS 14
Virtual LIVE: November 20 (Sat) 10:30 - 11:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Various aspects of asthma
Session
summary: In this symposium, we would
like to discuss asthma from various aspects. Although many asthma patients
benefit from inhaled corticosteroids therapy, some patients who has
steroid-resistant asthma do not. Firstly, we would like to discuss the
mechanism of steroid-resistant
asthma. In addition, neutrophil airway inflammation is considered to be
involved in steroid-resistant asthma, and respiratory microbiome analysis is an
important potential contributor to treatable traits approach. Finally, we would
like to learn a role of regulatory B cells to dampen the allergic immune
response in patients with asthma.
Chairs: Norihiro Harada (Juntendo
University Faculty of Medicine and Graduate School of Medicine, Japan)
Takashi Iwanaga (Kindai
University Hospital, Japan)
1)
Steroid-resistant asthma
Tomohito Takeshige (Juntendo
University Faculty of Medicine and Graduate School of Medicine, Japan)
2)
Microbiome in asthma
Steven L Taylor (South
Australian Health and Medical Research Institute, Australia)
3)
Regulatory and IgE + B cells in asthma
John-Paul Oliveria (McMaster
University, Canada)
15. ETS 15
Virtual LIVE: November 20 (Sat) 10:30 - 11:25 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
From the Bench of Young Basic Researchers
- Development of New Therapeutic Targets for
Pulmonary Hypertension
Session
summary: In recent years, many drugs
targeting endothelin, nitric oxide, and prostacyclin pathways have been used to
treat pulmonary hypertension (PH), and treatment outcomes have improved
dramatically. However, the prognosis of patients who are refractory to these
drugs remains poor. In addition, these drugs do not have sufficient effect on
advanced vascular remodeling. Therefore, new approaches other than vasodilators
are required to elucidate the pathogenesis and treatment of PH. In this
session, we will invite young investigators on PH to report their latest
research from the bench. We look forward to a lively discussion that is not
bound by existing concepts.
Chairs: Sachiko Kuriyama (Juntendo
University, Japan)
Lei Wang (Second
Affiliated Hospital of Xi'an Jiaotong University, China)
1)
Periostin contribute to the development of vascular remodeling via
enhanced M2
macrophage migration in pulmonary arterial hypertension
Takashi Yoshida (Juntendo
University, Japan)
2)
The role of PD-1/PD-L1 pathway in hypoxic pulmonary hypertension and its
possible
mechanism
Lei Wang (Second
Affiliated Hospital of Xi'an Jiaotong University, China)
3)
Gut microbiota in pulmonary hypertension
Takayuki Jujo (Graduate
School of Medicine, Chiba University, Japan)
16. ETS 16
Virtual LIVE: November 20 (Sat) 15:05 - 16:00 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Microenvironment in lung: The Disruption of
Homeostasis in Lung Disease
Session
summary: Since lung is always exposed
to outside, the specific homeostatic mechanisms contributes to lung health. The
repeated stimulation and aging process would bring cell dysfunction in lung,
followed by disease initiation. In this session, we aim to show the lung
disease pathogenesis in the point of microenvironment disorder, represented by
cell-cell interaction and cell-cell communication.
Chairs: Atsuyasu Sato (Kyoto
University, Japan)
Nakwon Kwak (Seoul
National University Hospital, South Korea)
1)
Lung Regeneration and Microenvironment
Atsuyasu Sato (Kyoto
Uiniversity, Japan)
2)
COPD pathgoenesis and microenvironment
Nakwon Kwak (Seoul
National University Hospital, South Korea)
3)
Disease Pathogenesis and Microenvironment in IPF
Rachel S. Knipe (Massachusetts General Hospital,
USA)
17. ETS 17
Virtual LIVE: November 20 (Sat) 15:05 - 16:00 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
2nd line treatment for EGFR-positive NSCLC:
beyond PD after osimertinib
Session
summary: The discovery of activating mutations
in the EGFR gene and the development of EGFR-TKIs have led to a paradigm shift
in the treatment of non-small cell lung cancer. Undoubtedly, the
third-generation EGFR-TKI, osimertinib, has promising efficacy and is the
mainstay of first line treatment. However, most patients become resistant to
osimertinib and relapse; hence, reliable treatment beyond resistance after
osimertinib is important for achieve a radical cure. In this session, we will
summarize and provide the current status of treatment strategies after
osimertinib resistance and the role of ICI for EGFR mutation-positive lung
cancer. In addition, we will discuss the latest treatments expected from the
perspective of acquired resistance mutation after treatment of osimertinib.
Chairs: Yukari Tsubata (Shimane
University, Japan)
Fariz Nurwidya (University of Indonesia, Indonesia)
1)
Treatment for EGFR-positive NSCLC
Motoko Tachihara (Kobe
University Graduate School of Medicine, Japan)
2)
Role of ICI for EGFR-positive NSCLC
Satoshi Ikeda (Kanagawa
Cardiovascular and Respiratory Center, Japan)
3)
Acquired resistance mutation after treatment of osimertinib
Fariz Nurwidya (University
of Indonesia, Indonesia)
18. ETS 18
Virtual LIVE: November 20 (Sat) 15:05 - 16:00 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Comprehensive analysis with liquid biopsy on
lung cancer
Session
summary: Liquid biopsy, especially
with circulating tumor DNA (ctDNA) has become widely applied in clinical
settings in step with progress in innovative technologies such as next
generation sequencing. The purposes of liquid biopsy range from identifying
markers of tumor progression to investigating mechanisms of acquired or
intrinsic resistance to agents of molecular targeted therapy. The former role
is an alternative to tumor markers, and the latter is an innovative diagnostic
tool that can be used to implement precision medicine. In this symposium, the
significance of liquid biopsy on lung cancer and how to use the technique will
be discussed based on the presentations by the specialists from various Asian
countries.
Chairs: Naoko Aragane (Saga
University Hospital, Japan)
Wang Chun Kwok (Queen
Mary Hospital, Hong Kong)
1)
Clinical usefulness of NGS with liquid biopsy
Chiho Nakashima (Saga
University, Japan)
2)
Plasma EGFR mutation status by ddPCR in patients with suspectedlung
canser-a prospective study in Hong Kong
Lynn Yim Wah
Shong (Kwong Wah Hospital, HKSAR,
China)
3)
Comprehensive Analysis with liquid biopsy on lung cancer
Luan Van Pham (108 Military
Central Hospital, Vietnam)
19. ETS 19
Virtual LIVE: November 20 (Sat) 15:05 - 16:00 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Lung epithelial regeneration: the
necessary approach for the future treatment
of pulmonary fibrosis
Session
summary: Numerous clinical trials
have been conducted over the last decades, resulting in approval of nintedanib
and pirfenidone for the treatment of idiopathic pulmonary fibrosis now.
However, these antifibrotic drugs do not restore the lung function in patients.
Therefore, to develop a better therapeutic strategy for pulmonary fibrosis, this
session will discuss current approaches that attempt to regenerate lung
epithelial cells. This session will address the following topics: the models or
platforms to study about epithelial regeneration of the lungs, the effect of
ARV825 on lung epithelial regeneration, and the regulation of lung alveolar
progenitor cell proliferation and differentiation by Gremlin.
Chairs: Seidai Sato (Graduate
School of Biomedical Sciences, Tokushima University, Japan)
Amornpun Wongkarnjana (King Chulalongkorn Memorial Hospital, Thailand)
1) Novel senolytic drug ARV-825
promotes self-renewal of alveolar type 2 cells in lung
Seidai Sato (Graduate School of Biomedical Sciences, Tokushima
University, Japan)
2) The
models and platforms to study about epithelial regeneration of the lungs in
lung fibrosis
Harshana Bandara Lansakara
Mudiyanselage (National
Hospital for Respiratory Diseases-Welisara, Sri Lanka)
3)
Intrinsic BMP inhibitor Gremlin regulates lung alveolar progenitor cell
proliferation
and differentiation
Toyoshi
Yanagihara (Hamanomachi Hospital, Japan)
20. ETS 20
Virtual LIVE: November 20 (Sat) 16:05 - 17:00 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Chronic airway diseases revisited 2021
Session
summary: Currently, the overlapping
and differential diagnosis of COPD and asthma is problematic and one of the hot
topics in chronic airway diseases. In this context, the management based on
treatable traits has been discussed. Another important chronic airway disease,
bronchiectasis, has also been paid attention in recent years as evidence from
disease registries and clinical trials has accumulated. Importantly, COPD and
asthma can be accompanied by bronchiectasis. Therefore, it is now time to
reconsider the chronic airway diseases comprehensively. In this symposium,
current topics on COPD, asthma, bronchiectasis, and their overlaps will be
discussed.
Chairs: Masaru Suzuki (Hokkaido
University, Japan)
Hye Yun Park (Samsung
Medical Center, South Korea)
1)
Reconsideration of COPD, asthma, and their overlap
Masaru Suzuki (Hokkaido
University, Japan)
2)
Significance of eosinophils in COPD
Hye Yun Park (Samsung Medical
Center, South Korea)
3)
Significance of bronchiectasis as a chronic airway disease
Sei Won Lee (Asan Medical
Center, South Korea)
21. ETS 21
Virtual LIVE: November 20 (Sat) 16:05 - 17:00 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Management of lung cancer in the next decade
Session
summary: The diagnosis and treatment
of lung cancer have been developed dramatically in recent decades. Discovery of
driver oncogenes and their specific inhibitors, introduction of immunotherapy
to clinical practice, and improvement of diagnostic modality like FDG-PET are
examples of them, and they have improved prognosis of lung cancer patients. In
this session, we will discuss how treatment and diagnosis of lung cancer will
change in the next decade, focusing on the field of chemotherapy including
molecular targeted agents and immunotherapy, radiotherapy, and pathology
Chair: Takehito Shukuya (Juntendo
University, Japan)
1)
Chemotherapy for lung cancer in the next decade
Yasushi Goto (National
Cancer Center Hospital, Japan)
2)
Radiotherpy for lung cancer in the next decade
Hideyuki Harada (Shizuoka
Cancer Center, Japan)
3)
Biomarker analysis for lung cancer in the next decade
Junya Fujimoto (The
University of Texas MD Anderson Cancer Center, USA)
22. ETS 22
Virtual LIVE: November 20 (Sat) 16:05 - 17:00 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Future in oncoimmunology against thoracic
cancer
Session
summary: Due to the clinical
application of immune checkpoint inhibitors, immunotherapy has achieved a
significant impact on the treatment of thoracic malignancies. This Emerging
Talent Symposium at APSR2021 features Immunotherapy and Cancer immunology on
thoracic cancers. The goal of this symposium is to bring together diverse
aspects of basic and clinical cancer immunology to help us better understand
how to use the immune system to treat cancer. In this program, researchers will
present their prospects on novel immune therapies, biomarkers for immune
checkpoint inhibitors, and novel approaches to cancer immunity against thoracic
cancer.
Chairs: Nobuaki Kobayashi (Yokohama
City University Graduate School of Medicine, Japan)
Zhang Xiaotong
(Peking Union Medical College, China)
1)
Synthetic oligonucleotides for cancer immunotherapy
Nobuaki Kobayashi (Yokohama
City University Graduate School of Medicine, Japan)
2)
Challenges for the establishment of biomarkers for immunotherapy in lung
cancer
Zhang Xiaotong (Peking Union
Medical College, China)
3)
For a better understanding of Immune checkpoint inhibitors from clinical
trials
Niels Reinmuth (Asklepios
Kliniken GmbH & Co., Germany)
Virtual LIVE: November 20
(Sat) 16:05 - 17:00 (JST/UTC+9)
On-demand: November 26 –
December 28, 2021
Nation-wide multicenter studies for Chronic Obstructive Pulmonary Disease
Session summary: Chronic obstructive pulmonary disease (COPD) is a common lung disease in
worldwide and known as a heterogeneous disease which have a various phenotype
and pathophysiology. To understand its pathophysiology, it is required to
consider such heterogeneity in clinical and basic research. Heterogeneity may
exist in local distribution of patients, and patients�ｿｽf habitus, lifestyle, and
culture even in one particular country. For this reason, the importance of
multicenter nation-wide studies has received a great attention in recent years,
and many reports have been made. In this session we can discuss these data in
countries from Asia-Pacific region and future direction.
Chairs: Susumu Sato (Graduate school of medicine, Kyoto University, Japan)
Yeon-Mok Oh (Asan
Medical Center, South Korea)
1) Knowledges from COPD cohort
studies in Japan
Naoya Tanabe (Kyoto University, Japan)
2) Knowledges from COPD cohort
studies in Korean
Chin Kook Rhee (Seoul St. Mary's Hospital, The Catholic University of
Korea, South Korea)
24. ETS 24
Virtual LIVE: November 20 (Sat) 17:05 - 18:00 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Challenges to prevent and control the outbreak
of COVID-19 and other
respiratory tract infections in different
countries
Session
summary: We have experienced the
COVID-19 pandemic that is life-threating for people all over the world. For more than one and a half years, we
have made a great effort to find effective therapeutic agents and treatment
strategies and effective preventive strategies.
Objectives of this symposium
are below:
- To share challenges to
prevent and control the outbreak of COVID-19 and other respiratory tract
infections in different countries
- To share lessons from both
success and failure, e.g., development of systems for research, clinical
trials, etc.
- Then, we are going to
discuss what we should do in order to overcome next wave of COVID-19 and other
emerging respiratory tract infections in the future.
Chairs: Yuichiro Shindo (Nagoya University
Hospital, Japan)
Yeming Wang (China-Japan Friendship Hospital, China)
1)
Epidemiological characteristics and therapeutic challenges in COVID-19 in
Japan
Yuichiro Shindo (Nagoya
University Hospital, Japan)
2)
Epidemiological characteristics and therapeutic/preventive challenges
in COVID-19
in other Asian areas (China,
Korea, etc)
Yeming
Wang (China-Japan Friendship Hospital, China)
3)
Epidemiological
characteristics and therapeutic/preventive challenges in COVID-19
in European
countries
James D. Chalmers (University of
Dundee, UK)
25. ETS 25
Virtual LIVE: November 20 (Sat) 17:05 - 18:00 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
The development of a novel therapeutic strategy
for lung cancer; from bench
to bedside
Session
summary: The intervention of systemic
therapy for lung cancer cells has accelerated tumor evolution and leads to be
acquired resistance. In addition, some patients are refractory to these
therapies. Therefore, primary therapeutic intervention has a crucial role for
the clinical outcome of such patients. Currently, promising novel strategies
are being developed in clinical trials. In this symposium, we will discuss the
cutting-edge for development of a novel therapeutic strategy in lung cancer,
based on molecular biological aspects.
Chairs: Tadaaki Yamada (Kyoto
Prefectural University of Medicine, Japan)
In-Jae Oh (Chonnam
National University Hwasun Hospital, South Korea)
1)
Overcoming drug tolerance to ALK inhibitor in ALK positive lung cancer
Keiko Tanimura (Kyoto
Prefectural University of Medicine, Japan)
2)
EGFR-TKIs resistance promotes immune escape in lung cancer via increased
PD-L1
expression
Wei Wang (Nanfang Hospital, Southern Medical University, China)
3)
Co-Mutation in splicing factor with EGFR mutations limits sensitivity to
EGFR-TKIs~Why are EGFR-TKIs less effective against EGFR L858R?
Shigeki Nanjo (Kanazawa University, Japan / UCSF, USA)
26. ETS 26
Virtual LIVE: November 20 (Sat) 17:05 - 18:00 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
How to detect driver mutations of lung cancer
in clinical practice
-current status and efforts-
Session
summary: Examination of genetic
alterations is essential for patients with advanced non–small cell lung cancer
(NSCLC). To detect mutations, there are methods using single plex and multiplex
cancer gene panel test by Next-generation sequencing (NGS) assay. NGS enables
the detection of large numbers of gene alterations simultaneously. But, The NGS
tests require appropriate tissue size and tumor cell content. We want to share
the current status of biomarker tests for driver mutations in clinical practice
of each country and efforts to increase the success rate of NGS analysis.
Chairs: Motoko Tachihara (Kobe
University Graduate School of Medicine, Japan)
Satoru Miura (Niigata Cancer Center Hospital,
Japan)
1)
Current Status and Initiatives at Matsusaka Municipal Hospital
Yoichi Nishii (Matsusaka Municipal Hospital Respiratory
Center, Japan)
2)
DETECTION OF ONCOGENIC DRIVER MUTATIONS IN THE UNITED STATES
Adam Fox (The Medical University of South Carolina, USA)
27. ETS 27
Virtual LIVE: November 20 (Sat) 17:05 - 18:00 (JST/UTC+9)
On-demand: November 26 – December 28, 2021
Review of BAL in Interstitial Lung Disease
diagnosis
Session
summary: In recent years, the
usefulness of bronchoalveolar lavage fluid (BALF) has been increasing, and the
IPF and HP guidelines are reviewing the evaluation of cellular components as
important information for definitive diagnosis. In addition to diagnostic
evaluation using cell fractions, research is also being conducted to explore
pathogenesis and etiology, such as microbiome and proteome analysis using
liquid components. We should discuss the clinical significance of BAL from
various perspectives in order to develop research using BALF.
Chairs: Yuko Waseda (University
of Fukui, Japan)
Sun Mi Choi (Seoul
National University Hospital, Seoul, South Korea)
1)
Morphological evaluation of BAL
Yuko Waseda (University
of Fukui, Japan)
2)
Evaluation of liquid component of BAL
Sun Mi Choi (Seoul
National University Hospital, Seoul, South Korea)
3)
Evaluation of cellular component of BAL
Sara Tomassetti (Careggi University Hospital,
Italy)